Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheet (Parenthetical)

v3.22.1
Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Assets    
Federal funds sold and securities borrowed or purchased under agreements to resell measured at fair value $ 174,685 $ 150,665
Trading account assets, pledged as collateral 118,191 103,434
Debt securities:    
Fair Value 620,876 665,890
Loans and leases, measured at fair value 7,111 7,819
Loans held for sale, measured at fair value 3,203 4,455
Other assets, measured at fair value 12,807 12,144
Deposits in U.S. offices:    
Interest bearing, measured at fair value 446 408
Federal funds purchased and securities loans or sold under agreements to repurchase, at fair value 155,239 139,641
Short-term borrowings, measured at fair value 3,487 4,279
Accrued expenses and other liabilities, measured at fair value 12,053 11,489
Accrued expenses and other liabilities, reserve for unfunded lending commitments 1,379 1,456
Long-term debt, measured at fair value $ 30,459 $ 29,708
Shareholders’ equity    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock authorized (in shares) 100,000,000 100,000,000
Preferred stock issued (in shares) 4,037,686 3,939,686
Preferred stock outstanding (in shares) 4,037,686 3,939,686
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock authorized (in shares) 12,800,000,000 12,800,000,000
Common stock issued (in shares) 8,062,102,236 8,077,831,463
Common stock outstanding (in shares) 8,062,102,236 8,077,831,463
Short-term borrowings | Consolidated VIEs    
Shareholders’ equity    
Non-recourse debt $ 32 $ 51
Long-term debt | Consolidated VIEs    
Shareholders’ equity    
Non-recourse debt 3,557 3,587
Other liabilities | Consolidated VIEs    
Shareholders’ equity    
Non-recourse debt $ 5 $ 7